Immune checkpoint inhibitor-induced sarcoidosis-like granulomas

Pooja H. Rambhia, Barbara Reichert, Jeffrey Scott, Ashley N. Feneran, Jordan A. Kazakov, Kord Honda, Henry Koon, Meg R. Gerstenblith

Research output: Contribution to journal › Review article

Abstract

Immune checkpoint inhibitors targeting the cytotoxic T lymphocyte-associated antigen-4 and programmed cell death-1 receptors have transformed the treatment of melanoma and other cancers. These therapies are associated with a number of side effects, including immune-related adverse events. Sarcoidosis-like granulomas (SLGs) are important immune checkpoint inhibitor-related reactions to recognize as SLGs can mimic disease progression and accordingly impact treatment decisions. We systematically review reports of immune checkpoint inhibitor-induced SLGs in cancer patients and discuss potential underlying pathophysiological mechanisms.

Original languageEnglish (US)
JournalInternational Journal of Clinical Oncology
DOIs
StateAccepted/In press - Jan 1 2019
Externally publishedYes

Fingerprint

Sarcoidosis
Granuloma
Programmed Cell Death 1 Receptor
CTLA-4 Antigen
Disease Progression
Melanoma
Neoplasms
Therapeutics

Keywords

  • CTLA-4
  • Drug reactions
  • Immune checkpoint inhibitor
  • Melanoma
  • PD-1
  • Sarcoidosis-like granuloma

ASJC Scopus subject areas

  • Surgery
  • Hematology
  • Oncology

Cite this

Rambhia, P. H., Reichert, B., Scott, J., Feneran, A. N., Kazakov, J. A., Honda, K., ... Gerstenblith, M. R. (Accepted/In press). Immune checkpoint inhibitor-induced sarcoidosis-like granulomas. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-019-01490-2

Immune checkpoint inhibitor-induced sarcoidosis-like granulomas. / Rambhia, Pooja H.; Reichert, Barbara; Scott, Jeffrey; Feneran, Ashley N.; Kazakov, Jordan A.; Honda, Kord; Koon, Henry; Gerstenblith, Meg R.

In: International Journal of Clinical Oncology, 01.01.2019.

Research output: Contribution to journal › Review article

Rambhia, PH, Reichert, B, Scott, J, Feneran, AN, Kazakov, JA, Honda, K, Koon, H & Gerstenblith, MR 2019, 'Immune checkpoint inhibitor-induced sarcoidosis-like granulomas', International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-019-01490-2
Rambhia PH, Reichert B, Scott J, Feneran AN, Kazakov JA, Honda K et al. Immune checkpoint inhibitor-induced sarcoidosis-like granulomas. International Journal of Clinical Oncology. 2019 Jan 1. https://doi.org/10.1007/s10147-019-01490-2
Rambhia, Pooja H. ; Reichert, Barbara ; Scott, Jeffrey ; Feneran, Ashley N. ; Kazakov, Jordan A. ; Honda, Kord ; Koon, Henry ; Gerstenblith, Meg R. / Immune checkpoint inhibitor-induced sarcoidosis-like granulomas. In: International Journal of Clinical Oncology. 2019.
@article{126db2ee9db841e4a8126cbd2e606540,
title = "Immune checkpoint inhibitor-induced sarcoidosis-like granulomas",
abstract = "Immune checkpoint inhibitors targeting the cytotoxic T lymphocyte-associated antigen-4 and programmed cell death-1 receptors have transformed the treatment of melanoma and other cancers. These therapies are associated with a number of side effects, including immune-related adverse events. Sarcoidosis-like granulomas (SLGs) are important immune checkpoint inhibitor-related reactions to recognize as SLGs can mimic disease progression and accordingly impact treatment decisions. We systematically review reports of immune checkpoint inhibitor-induced SLGs in cancer patients and discuss potential underlying pathophysiological mechanisms.",
keywords = "CTLA-4, Drug reactions, Immune checkpoint inhibitor, Melanoma, PD-1, Sarcoidosis-like granuloma",
author = "Rambhia, {Pooja H.} and Barbara Reichert and Jeffrey Scott and Feneran, {Ashley N.} and Kazakov, {Jordan A.} and Kord Honda and Henry Koon and Gerstenblith, {Meg R.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s10147-019-01490-2",
language = "English (US)",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",

}

TY - JOUR

T1 - Immune checkpoint inhibitor-induced sarcoidosis-like granulomas

AU - Rambhia, Pooja H.

AU - Reichert, Barbara

AU - Scott, Jeffrey

AU - Feneran, Ashley N.

AU - Kazakov, Jordan A.

AU - Honda, Kord

AU - Koon, Henry

AU - Gerstenblith, Meg R.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Immune checkpoint inhibitors targeting the cytotoxic T lymphocyte-associated antigen-4 and programmed cell death-1 receptors have transformed the treatment of melanoma and other cancers. These therapies are associated with a number of side effects, including immune-related adverse events. Sarcoidosis-like granulomas (SLGs) are important immune checkpoint inhibitor-related reactions to recognize as SLGs can mimic disease progression and accordingly impact treatment decisions. We systematically review reports of immune checkpoint inhibitor-induced SLGs in cancer patients and discuss potential underlying pathophysiological mechanisms.

AB - Immune checkpoint inhibitors targeting the cytotoxic T lymphocyte-associated antigen-4 and programmed cell death-1 receptors have transformed the treatment of melanoma and other cancers. These therapies are associated with a number of side effects, including immune-related adverse events. Sarcoidosis-like granulomas (SLGs) are important immune checkpoint inhibitor-related reactions to recognize as SLGs can mimic disease progression and accordingly impact treatment decisions. We systematically review reports of immune checkpoint inhibitor-induced SLGs in cancer patients and discuss potential underlying pathophysiological mechanisms.

KW - CTLA-4

KW - Drug reactions

KW - Immune checkpoint inhibitor

KW - Melanoma

KW - PD-1

KW - Sarcoidosis-like granuloma

UR - http://www.scopus.com/inward/record.url?scp=85069503866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069503866&partnerID=8YFLogxK

U2 - 10.1007/s10147-019-01490-2

DO - 10.1007/s10147-019-01490-2

M3 - Review article

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

ER -

Access to Document